Published in Rheum Dis Clin North Am on November 01, 2009
Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum (2007) 3.12
Systematic review of studies of productivity loss due to rheumatoid arthritis. Occup Med (Lond) (2005) 2.51
Hotel-based medicine. J Rheumatol (2008) 2.04
Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arthritis Res Ther (2009) 1.87
Physical inactivity in patients with rheumatoid arthritis: data from twenty-one countries in a cross-sectional, international study. Arthritis Rheum (2008) 1.51
Quantitative clinical rheumatology: why is a test for anti-CCP antibodies included in most routine care for rheumatoid arthritis while a HAQ/MDHAQ remains largely a research tool? J Rheumatol (2009) 1.43
Incomplete reporting of recruitment information in clinical trials of biologic agents for the treatment of rheumatoid arthritis: a review. Arthritis Care Res (Hoboken) (2012) 1.41
N-of-1 trial of low-dose methotrexate and/or prednisolone in lieu of anti-CCP, MRI, or ultrasound, as first option in suspected rheumatoid arthritis? J Rheumatol (2007) 1.39
Prospects for disease modification in osteoarthritis. Nat Clin Pract Rheumatol (2006) 1.33
Utilization trends of tumor necrosis factor inhibitors among patients with rheumatoid arthritis in a United States observational cohort study. J Rheumatol (2009) 1.28
Visual analog scales in formats other than a 10 centimeter horizontal line to assess pain and other clinical data. J Rheumatol (2008) 1.27
RAPID3 (Routine Assessment of Patient Index Data 3) severity categories and response criteria: Similar results to DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural Damage) clinical trial of certolizumab pegol. Arthritis Care Res (Hoboken) (2011) 1.12
Apremilast for Behçet's syndrome--a phase 2, placebo-controlled study. N Engl J Med (2015) 1.11
The direct and indirect cost burden of Crohn's disease and ulcerative colitis. J Occup Environ Med (2008) 1.10
The direct and indirect cost burden of acute coronary syndrome. J Occup Environ Med (2011) 1.08
When is it not ethical to withhold treatment for rheumatoid arthritis? Ann Rheum Dis (2013) 1.07
A proposed continuous quality improvement approach to assessment and management of patients with rheumatoid arthritis without formal joint counts, based on quantitative routine assessment of patient index data (RAPID) scores on a multidimensional health assessment questionnaire (MDHAQ). Best Pract Res Clin Rheumatol (2007) 1.06
A practical guide to scoring a Multi-Dimensional Health Assessment Questionnaire (MDHAQ) and Routine Assessment of Patient Index Data (RAPID) scores in 10-20 seconds for use in standard clinical care, without rulers, calculators, websites or computers. Best Pract Res Clin Rheumatol (2007) 1.04
RAPID3 (Routine Assessment of Patient Index Data) on an MDHAQ (Multidimensional Health Assessment Questionnaire): agreement with DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) activity categories, scored in five versus more than ninety seconds. Arthritis Care Res (Hoboken) (2010) 1.03
Item response theory methods can improve the measurement of physical function by combining the modified health assessment questionnaire and the SF-36 physical function scale. Qual Life Res (2007) 1.02
Behcet's Syndrome. Drugs (2012) 1.02
RAPID3, an index to assess and monitor patients with rheumatoid arthritis, without formal joint counts: similar results to DAS28 and CDAI in clinical trials and clinical care. Rheum Dis Clin North Am (2009) 1.01
Patient questionnaires in rheumatoid arthritis: advantages and limitations as a quantitative, standardized scientific medical history. Rheum Dis Clin North Am (2009) 1.00
Biologics in development for rheumatoid arthritis: relevance to osteoarthritis. Adv Drug Deliv Rev (2006) 1.00
Behçet's syndrome. Rheum Dis Clin North Am (2013) 0.99
Quantitative measures of rheumatic diseases for clinical research versus standard clinical care: differences, advantages and limitations. Best Pract Res Clin Rheumatol (2007) 0.97
The impact of rheumatoid arthritis on medical expenditures, absenteeism, and short-term disability benefits. J Occup Environ Med (2006) 0.95
Neoplasms as the leading cause of death among patients with rheumatoid arthritis receiving tumor necrosis factor inhibitors: comment on the article by Simard et al. Arthritis Rheum (2013) 0.95
Reevaluation of the role of duration of morning stiffness in the assessment of rheumatoid arthritis activity. J Rheumatol (2009) 0.93
Patient-driven assessment of disease activity in Behçet's syndrome: cross-cultural adaptation, reliability and validity of the Turkish version of the Behçet's Syndrome Activity Score. Clin Exp Rheumatol (2013) 0.93
Parenteral methotrexate for the treatment of rheumatoid arthritis. Bull Hosp Jt Dis (2013) (2013) 0.92
RAPID3-an index of physical function, pain, and global status as "vital signs" to improve care for people with chronic rheumatic diseases. Bull NYU Hosp Jt Dis (2009) 0.91
Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-alpha antagonists. J Rheumatol (2008) 0.90
Peripheral arterial disease and renal transplantation. J Am Soc Nephrol (2006) 0.89
Proposed severity and response criteria for Routine Assessment of Patient Index Data (RAPID3): results for categories of disease activity and response criteria in abatacept clinical trials. J Rheumatol (2011) 0.88
Treat-to-target: not as simple as it appears. Clin Exp Rheumatol (2012) 0.88
Racial and ethnic disparities in disease activity in patients with rheumatoid arthritis. Am J Med (2013) 0.87
Indirect cost-effectiveness analyses of abatacept and rituximab in patients with moderate-to-severe rheumatoid arthritis in the United States. J Med Econ (2010) 0.86
Utility of the new rheumatoid arthritis 2010 ACR/EULAR classification criteria in routine clinical care. BMJ Open (2012) 0.86
Fatal acute necrotizing eosinophilic myocarditis temporally related to use of adalimumab in a patient with relapsing polychondritis. J Clin Rheumatol (2013) 0.85
Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDS and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis. Clin Rheumatol (2008) 0.84
MDHAQ/RAPID3 to recognize improvement over 2 months in usual care of patients with osteoarthritis, systemic lupus erythematosus, spondyloarthropathy, and gout, as well as rheumatoid arthritis. J Clin Rheumatol (2013) 0.83
Monitoring methotrexate hepatic toxicity in rheumatoid arthritis: is it time to update the guidelines? J Rheumatol (2002) 0.83
Patient self-report RADAI (Rheumatoid Arthritis Disease Activity Index) joint counts on an MDHAQ (Multidimensional Health Assessment Questionnaire) in usual care of consecutive patients with rheumatic diseases other than rheumatoid arthritis. Arthritis Care Res (Hoboken) (2013) 0.83
Differences in clinical manifestations, treatment, and concordance rates with two major sets of criteria for Behçet's syndrome for patients in the US and Japan: data from a large, three-center cohort study. Mod Rheumatol (2012) 0.83
Discordance of global estimates by patients and their physicians in usual care of many rheumatic diseases: association with 5 scores on a Multidimensional Health Assessment Questionnaire (MDHAQ) that are not found on the Health Assessment Questionnaire (HAQ). Arthritis Care Res (Hoboken) (2014) 0.82
Value of survival gains in chronic myeloid leukemia. Am J Manag Care (2012) 0.82
Prevalence and patterns of concomitant use of selective serotonin reuptake inhibitors and other antidepressants in a high-cost polypharmacy cohort. Clin Ther (2002) 0.82
Time to psychiatric hospitalization in patients with bipolar disorder treated with a mood stabilizer and adjunctive atypical antipsychotics: a retrospective claims database analysis. Clin Ther (2009) 0.82
Complexities in assessment of rheumatoid arthritis: absence of a single gold standard measure. Rheum Dis Clin North Am (2009) 0.81
Pragmatic and scientific advantages of MDHAQ/ RAPID3 completion by all patients at all visits in routine clinical care. Bull NYU Hosp Jt Dis (2012) 0.81
Development and validation of a short form of the valued life activities disability questionnaire for rheumatoid arthritis. Arthritis Care Res (Hoboken) (2011) 0.81
Radiographic benefit without clinical improvement in infliximab-treated patients with rheumatoid arthritis: comment on the article by Smolen et al. Arthritis Rheum (2005) 0.80
How to collect an MDHAQ to provide rheumatology vital signs (function, pain, global status, and RAPID3 scores) in the infrastructure of rheumatology care, including some misconceptions regarding the MDHAQ. Rheum Dis Clin North Am (2009) 0.80
Trial of etanercept and methotrexate with radiographic and patient outcomes two-year clinical and radiographic results: Comment on the article by van der Heijde et al. Arthritis Rheum (2006) 0.80
Treatment of rheumatoid arthritis: strategies for achieving optimal outcomes. Ann Rheum Dis (2010) 0.80
Beyond RAPID3 - practical use of the MDHAQ to improve doctor-patient communication. Bull NYU Hosp Jt Dis (2010) 0.79
A patient-reported outcome measures-based composite index (RAPID3) for the assessment of disease activity in ankylosing spondylitis. Rheumatol Int (2015) 0.79
Rheumatoid arthritis: When should we use rituximab to treat RA? Nat Rev Rheumatol (2011) 0.79
Why are only 50% of courses of anti-tumor necrosis factor agents continued for only 2 years in some settings? Need for longterm observations in standard care to complement clinical trials. J Rheumatol (2006) 0.79
Inpatient mortality: a reflection of quality care? Outcomes Manag (2002) 0.78
Productivity cost model of the treatment of rheumatoid arthritis with abatacept. J Med Econ (2008) 0.78
Focus group data as a tool in assessing effectiveness of a hand hygiene campaign. Am J Infect Control (2005) 0.77
Improvement Thresholds for Morning Stiffness Duration in Patients Receiving Delayed- Versus Immediate-Release Prednisone for Rheumatoid Arthritis. Bull Hosp Jt Dis (2013) (2015) 0.77
Tools for monitoring remission in rheumatoid arthritis: any will do, let's just pick one and start measuring. Arthritis Res Ther (2013) 0.77
RHEUMDOC: a one-page RHEUMatology DOCtor form with four physician global estimates for overall status, inflammation, damage, and symptoms based on neither inflammation nor damage. Bull Hosp Jt Dis (2013) (2014) 0.77
Are excellent systematic reviews of clinical trials useful for patient care? Nat Clin Pract Rheumatol (2008) 0.77
Denosumab in postmenopausal women with low bone mineral density. N Engl J Med (2006) 0.77
A pilot study of feasibility and efficacy of telemedicine-delivered psychophysiological treatment for vascular headache. Telemed J E Health (2004) 0.76
Abatacept versus other biologics in methotrexate inadequate responders with rheumatoid arthritis: you like tomato and I like tomahto... let's call the whole thing off. Arthritis Res Ther (2012) 0.76
MDHAQ/RAPID3 can provide a roadmap or agenda for all rheumatology visits when the entire MDHAQ is completed at all patient visits and reviewed by the doctor before the encounter. Bull NYU Hosp Jt Dis (2012) 0.76
Headache in Behçet's syndrome: review of literature and NYU Behçet's syndrome center experience. Curr Pain Headache Rep (2014) 0.76
Comment on: Web resources for rare auto-inflammatory diseases: towards a common patient registry. Rheumatology (Oxford) (2009) 0.75
Quality control of a medical history: improving accuracy with patient participation, supported by a four-page version of the multidimensional health assessment questionnaire (MDHAQ). Rheum Dis Clin North Am (2009) 0.75
Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis. Ann Intern Med (2012) 0.75
Are we content that risk of cancer is not appreciably increased after tumor necrosis factor inhibitor use? Comment on the article by Solomon et al. Arthritis Rheum (2012) 0.75
Analysis of risk factors and comorbid diseases in the development of thrombosis in patients with anticardiolipin antibodies: comment on the article by Sairam et al. Clin Rheumatol (2003) 0.75
Necrotizing vasculitis--a 2009 update. Bull NYU Hosp Jt Dis (2009) 0.75
Eligibility of rheumatoid arthritis patients seen in clinical practice for rheumatoid arthritis clinical trials: comment on the article by Sokka and Pincus. Arthritis Rheum (2003) 0.75
Use of statistical analysis in open extension studies. J Rheumatol (2006) 0.75
Safety and clinical efficacy of golimumab in the treatment of arthritides. Drug Healthc Patient Saf (2010) 0.75
Rheumatoid arthritis: Evidence-based rather than habit-based treatment options. Nat Rev Rheumatol (2012) 0.75
Asymptomatic giant coronary aneurysm in an adolescent with Behcet's syndrome. Pediatr Rheumatol Online J (2012) 0.75
Diagnosis and/or classification of vasculitis: different? Curr Opin Rheumatol (2016) 0.75
An audit of Behcet's syndrome research: a 10-year survey. J Rheumatol (2010) 0.75
Coverage and use of cancer therapies in the treatment of chronic myeloid leukemia. Am J Manag Care (2012) 0.75
Finger and Wrist Pain in Children Using Game Consoles and Laptops Younger Children and Longer Time Are Associated with Increased Pain. Bull Hosp Jt Dis (2013) (2017) 0.75